Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.39 |
| ▸ | SYK | P43405 | 4/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23524413 | 0.89 | LRRK2 (0.37) | LRRK2SYKGSK3BKDM1ANPC1 | |
| SCHEMBL30355730 | 0.89 | LRRK2 (0.37) | LRRK2SYKGSK3BKDM1ANPC1 | |
| SCHEMBL25857252 | 0.87 | LRRK2 (0.35) | LRRK2SYKIRAK4 | |
| SCHEMBL25857251 | 0.85 | GSK3B (0.35) | RETGSK3BKDM1ANPC1POLB | |
| SCHEMBL30355580 | 0.81 | DYRK1A (0.42) | LRRK2SYKGSK3B | |
| SCHEMBL23524068 | 0.81 | DYRK1A (0.42) | LRRK2SYKGSK3B | |
| SCHEMBL30355542 | 0.76 | PGR (0.35) | LRRK2IRAK4 | |
| SCHEMBL23523921 | 0.76 | PGR (0.35) | LRRK2IRAK4 | |
| SCHEMBL23523920 | 0.76 | KDM1A (0.36) | GSK3BKDM1ANPC1POLBRAB9A | |
| SCHEMBL30355442 | 0.76 | KDM1A (0.36) | GSK3BKDM1ANPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | LRRK2 2882/4885SYK 661/4885RET 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.